Oncologist-Reported Barriers and Facilitators to Offering Cancer Clinical Trials to Their Patients.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
28 May 2024
Historique:
received: 26 04 2024
revised: 19 05 2024
accepted: 24 05 2024
medline: 26 6 2024
pubmed: 26 6 2024
entrez: 26 6 2024
Statut: epublish

Résumé

NCCN guidelines indicate that cancer clinical trials (CCTs) are the best management for patients with cancer. However, only 5% of patients enroll in them. We examined oncologists' perceived barriers and facilitators to discussing CCTs. This qualitative study was part of the ASCO-ACCC Initiative to Increase Racial and Ethnic Diversity in Clinical Trials. Barriers and facilitators at the system, trial, provider, and patient levels were examined. To achieve triangulation, patient encounters were reviewed using chart-stimulated recall (CSR) methods, thereby obtaining a valid assessment of physician performance. Ten oncology providers participated in this study. Nine were oncologists, and one was a clinical research coordinator; five were female; four were White; three were Asian; and three were Black. Barriers to offering CCTs were a lack of trial availability; ineligibility; a lack of knowledge; assumptions about patient interest, benefits, or harms; patient's disease factors; and negative attitudes. Facilitators of offering CCTs were a physical space to discuss trials; greater trial availability; a systematic approach to offering trials; patient factors; patients seeking trials; a lack of comorbidities; patients being younger in age; patients being aware of, asking about, or hearing of trials from their surgeon; and higher levels of altruism. Many of the cited barriers are addressable with the cited facilitators. A larger study is needed to generalize and validate these findings.

Identifiants

pubmed: 38920714
pii: curroncol31060230
doi: 10.3390/curroncol31060230
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3017-3029

Auteurs

Brenda S Castillo (BS)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Leigh Boehmer (L)

Association of Community Cancer Centers, Rockville, MD 20850, USA.

Janelle Schrag (J)

Whitman-Walker Institute, Washington, DC 20009, USA.

Alexandra Howson (A)

Thistle Editorial LLC., Snoqualmie, WA 98065, USA.

Randall Oyer (R)

Ann B. Barshinger Cancer Institute, Penn Medicine Lancaster General Health, Lancaster, PA 17601, USA.

Lori Pierce (L)

Rogel Comprehensive Cancer Center at the University of Michigan, Ann Arbor, MI 48109, USA.

Nadine J Barrett (NJ)

Duke Clinical and Translational Science Institute and Duke Cancer Institute, Durham, NC 27701, USA.

Carmen E Guerra (CE)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Leonard Davis Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH